Participant flow



Baseline characteristics

Demographic data	Enrolled, safety and adhesion set N=12	Pharmacokinetic set N=12
Sex		
Female - n (%)	6 (50%)	5 (50%)
Male – n (%)	6 (50%)	5 (50%)
Age (years)		
Mean ± SD	36.4±11	35.6±12
Median (min-max)	41.0 (20-52)	41.0 (20-52)
Body weight (kg)		
Mean ± SD	72.96±8.75	71.89±8.15
Median (min-max)	72.20 (57.6-87.7)	72.20 (57.6-85.1)
Height (cm)		
Mean ± SD	169.4±10.0	169.6±9.3
Median (min-max)	167.5 (156-183)	167.5 (158-183)
Body Mass Index (kg/m^2)		
Mean ± SD	25.46±2.14	24.99±1.98
Median (min-max)	25.95 (21.4-28.8)	25.45 (21.4-27.2)
Race		
White – n (%)	12 (100%)	10 (100%)

Outcome measures

Primary outcome

Mean (+SD) piroxicam plasma concentrations (ng/mL) measured in plasma at pre-application and at pre-specified time-points after last application of Flector Unidie® 14 mg medicated plaster is shown in the table below (N=10):

Time		Piroxicam concentrations (ng/mL)
Day 1	**Pre-application**	BLQL*
Day 2	**Pre-application**	1.693±1.344
Day 3	**Pre-application**	4.529±3.028*
Day 4	**Pre-application**	5.185±2.992
Day 5	**Pre-application**	5.716±3.133
	30 min	5.995±3.527
	1 h	5.780±3.175
	2 h	5.373±3.067**
	3 h	5.986±3.231
	4 h	5.734±3.490***
	6 h	5.435±3.066
	8 h	5.432±3.138*
	10 h	5.702±2.748
	12 h	6.620±3.531
	16 h	5.869±3.049
	24 h	6.109±3.471
	36 h	6.484±3.449
	48 h	5.014±2.886
	72 h	3.998±2.330

: N=9, **: N=8, *: N=7; BLQL: 0.10 ng/mL for subjects from study number 01-020/001 to 01-019/006 and 0.40 ng/mL for subjects from study number 01-016/007 to 01-011/012*

Descriptive statistics of piroxicam plasma pharmacokinetic parameters after 5 days repeated 24-h application of Flector Unidie® 14 mg medicated plaster are presented in the table below (N=10):

Pharmacokinetic parameter	Values
$C_{max0-24h}$ (ng/mL)	7.253±3.680
C_{24h} (ng/mL)	6.109±3.471
$C_{min0-24h}$ (ng/mL)	5.190±2.885
$C_{ave0-24h}$ (ng/mL)	5.939±3.103
$t_{max0-24h}$ (h)	12 (0.5-24)
AUC_{0-24h} (h*ng/mL)	142.526±74.478
AUC_{0-72} (h*ng/mL)	395.216±214.802
$AUC_{0-\infty}$ (h*ng/mL)	748.269±538.478*
Flu% [0-24h]	36.815±17.547
$t_{1/2}$ (h)	55.004±17.952*

*Values are arithmetic means ± SD, except for $t_{max0-24}$: median (min-max); *: N=9*

Secondary outcome

Results of Day 1 adhesion evaluations for Flector Unidie® 14 mg medicated plaster are reported overall in the table below (N=12):

Adhesion score	Overall n (%)
0 (≥ 90% adhered)	57 (95.0)
1 (≥ 75% to < 90% adhered)	3 (5.0)
2 (≥ 50% to < 75% adhered)	0 (0.0)
3 (> 0% to < 50% adhered)	0 (0.0)
4 (0% adhered)	0 (0.0)

Actual percentage values of plaster adhered area evaluated on Day 1 by the trained Investigator are summarised by descriptive statistics in the table below (N=12):

Time	Actual adhesion percentage (%) Arithmetic mean ± SD
Day 1 - 4 h	95.7±3.3
Day 1 - 8 h	94.8±3.5
Day 1 - 12 h	94.8±3.5
Day 1 – 16 h	94.9±3.4
Day 1 – 20 h	93.8±4.2
Overall – Day 1	94.8±3.5

Adverse events

Number of treatment-emergent adverse events (TEAEs) and number and percentage of subjects with TEAEs are presented by system organ class (SOC) and preferred term (PT) in the table below (Safety set, N=12)

SOC **PT**	**n** **AEs**	**n (%)** **subjects**
All TEAEs – all SOCs	4	3 (25.0)
General disorders and administration site conditions	2	2 (16.7)
Application site erythema	2	2 (16.7)
Nervous system disorders	1	1 (8.3)
Headache	1	1 (8.3)
Respiratory, thoracic and mediastinal disorders	1	1 (8.3)
Oropharyngeal pain	1	1 (8.3)

Number of TEAEs and number of subjects with TEAEs are presented in the table below (Safety set, N=12).

Category	**n** **AEs**	**n (%)** **subjects**
All TEAEs	4	3 (25.0)
Related	3	2 (16.7)
Not related	1	1 (8.3)
Leading to discontinuation	0	0 (0.0)
Serious adverse events	0	0 (0.0)